RNAZ

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Wall Street analysts forecast RNAZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAZ is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Transcode Therapeutics Inc revenue for the last quarter amounts to -4.54M USD, increased 110.78 % YoY.

Transcode Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

Transcode Therapeutics Inc (RNAZ) has 7 emplpoyees as of January 07 2026.

Today RNAZ has the market capitalization of 6.85M USD.